Company intelligence / Profile preview

Precision Biopsy

Colorado, United Statesauajournals.org ↗

Ownership: Private
Development stage: Other

Overview

Precision Biopsy developed the ClariCore Optical Biopsy System, which uses spectral analysis to provide real-time, in-vivo classification of prostate tissue. Clinical trials at the University of Colorado showed encouraging results in improving detection rates for prostate cancer. The system aims to reduce unnecessary biopsies by up to 90% and improve diagnostic accuracy. As of 2016, the company was preparing for international commercialization and further development of focal therapy programs targeting localized treatment within the prostate gland.

Therapeutic areas: Oncology
Modalities: DeviceDiagnostic technology (optical tissue classification)
Industry: Pathology

Partnerships

University of Colorado Denver/Urology DepartmentAllied MindsWoodford Investment Management

Beyond the preview

Go deeper on Precision Biopsy.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Precision Biopsy.

Explore the full profile